A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)

NCT06701513 · tracked via the Priya Life Science France tracker

Sponsor

Bristol-Myers Squibb

Phase

Observational

Started

2025-01-29

Last updated

2026-05-18

Condition(s) studied

Psoriasis

Investigational drug(s) / intervention(s)

Deucravacitinib →

Deucravacitinib: As prescribed by treating clinician

Study summary

The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * ≥18 years of age * Physician-reported diagnosis of moderate to severe plaque psoriasis * Be newly initiating deucravacitinib * Do not object to participate Exclusion Criteria: * Currently participating in or planning to participate in an interventional clinical trial * Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial

Primary outcome measure(s)

Physician's Global Assessment (PGA) 0/1 response — Baseline and at months 4, 12, 18 (optional), and 24
Dermatology Life Quality Index (DLQI) 0/1 response — Baseline and at months 4, 12, 18 (optional), and 24
Time from date of treatment initiation to date of discontinuation — Up to 24 months

Trial sites (48)

Facility	City	Region	Status
Chu Amiens Picardie - Site Sud	Amiens	France	Recruiting
Cabinet Médical Elisabeth Lion	Angers	France	Recruiting
Ch Victor Dupouy	Argenteuil	France	Recruiting
Local Institution - 089	Argenteuil	France	Completed
CH ARRAS	Arras	France	Recruiting
Cabinet Dermatologie	Bordeaux	France	Recruiting
Cabinet Dermatologie	Bordeaux	France	Recruiting
Centre Hospitalier William Morey - Hématologie	Chalon-sur-Saône	France	Recruiting
Local Institution - 053	Clermont-Ferrand	France	Completed
CHU Dijon	Dijon	France	Recruiting
Local Institution - 077	Dijon	France	Not Yet Recruiting
CHU Grenoble Alps, Service de Dermatologie	La Tronche	France	Recruiting
Local Institution - 014	Le Mans	France	Not Yet Recruiting
CH Emile Roux	Le Puy-en-Velay	France	Recruiting
Centre Hospitalier Lens	Lens	France	Recruiting
Centre de santé Filieris	Marcq-en-Barœul	France	Recruiting
Hopital Saint Eloi	Montpellier	France	Recruiting
Tagast 41	Nice	France	Recruiting
Ch Georges Renon	Niort	France	Recruiting
Ch Georges Renon	Niort	France	Recruiting
Hopital Caremeau	Nîmes	France	Recruiting
Cabinet de dermatologie	Paris	France	Recruiting
Local Institution - 086	Paris	France	Completed
Hôpital Privé Francheville	Périgueux	France	Recruiting
Centre Hospitalier de Roubaix	Roubaix	France	Recruiting
Centre Hospitalier de Roubaix	Roubaix	France	Recruiting
Local Institution - 031	Rouen	France	Completed
Local Institution - 065	Saint-Germain-en-Laye	France	Not Yet Recruiting
Hia Begin	Saint-Mandé	France	Recruiting
Centre Dermatologique	Saint-Maur-des-Fossés	France	Recruiting
Hia Sainte Anne	Toulon	France	Recruiting
Hia Sainte Anne	Toulon	France	Recruiting
Hopital Larrey	Toulouse	France	Recruiting
Hopital Larrey	Toulouse	France	Recruiting
Hopital Larrey	Toulouse	France	Recruiting
Hopitaux de Brabois	Vandœuvre-lès-Nancy	France	Recruiting
Hopitaux de Brabois	Vandœuvre-lès-Nancy	France	Recruiting
Médipôle Hôpital Mutualiste	Villeurbanne	France	Recruiting
Médipôle Hôpital Mutualiste	Villeurbanne	France	Recruiting
Cabinet Medical	La Chaux-de-Fonds	Switzerland	Recruiting

+ 8 more sites — see the full list on the official registry below.

More Bristol-Myers Squibb trials in France

Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE) Active, not recruiting

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy Recruiting

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome Active, not recruiting

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis Active, not recruiting

Other trials for the same condition

A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps Active, not recruiting

Cytokine Expression in Psoriasis Patients With and Without Joint Involvement Recruiting

Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata Enrolling by invitation

Characterization of the Fungal Immunopeptidome Involved in the Immunopathological Mechanisms of Psoriasis Starting soon

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06701513 on ClinicalTrials.gov ↗ ← All trials in France